Perspective Therapeutics, Inc. (CATX) Stock

Perspective Therapeutics, Inc. (CATX) is a Healthcare stock trading at $3.30 (as of 2026-08-21), with a market capitalization of $376.70M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.

Understand Perspective Therapeutics, Inc.: how it makes money

Perspective Therapeutics develops, manufactures, sells, and markets isotope-based medical products and devices for cancer treatment, including CS-1 Cesium-131 brachytherapy seeds sold to facilities and physician practices that use surgical treatment.

The company monetizes isotope-based cancer treatments by selling its medical products (such as CS-1 brachytherapy seeds) to treating facilities, so commercial momentum is tied to clinical performance and treatment uptake reflected in its trial outcome metrics.

Revenue by segment (latest quarter)
Grant Revenue	$0.0B

Business quality (Weak): In the latest provided period (2026-03-31), reported revenue is 0.0B with a very negative operating margin, so the provided financial snapshot alone does not clearly indicate operating progress.

Bull case

Clear, trackable efficacy signal in its VMT-alpha-NET program: Objective Response Rate in Cohort 2 is provided as 39.0% (Response Evaluation Criteria in Solid Tumors Version 1.1).
Safety outcome is specifically quantified: Grade 3 or Higher Treatment-Emergent Adverse Event Rate is provided as 37.5%, giving investors a defined measure of higher-severity events.

Bear case

Higher-severity adverse events could limit treatment adoption: The Grade 3 or Higher Treatment-Emergent Adverse Event Rate is 37.5%, which may raise clinician and patient concern for risk tolerance.
Near-term revenue visibility is limited in the provided financials: For 2026-03-31, the provided revenue is 0.0B and the operating margin is -1287.3, making it difficult to assess underlying commercial traction from this dataset alone.

Valuation — source: SEC EDGAR (first-party)
Price	$3.30
Market Cap	$376.70M
Price / Book	1.16
Price / Sales	43.31
FCF Yield	-57.2%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$8.11M
Net Margin	-1270.9%
Revenue Growth (YoY)	-22.8%
EPS Growth (YoY)	13.8%
FCF Growth (YoY)	31.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	1.17 (distress)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	TCG Crossover Management, LLC ($33.01M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Johan Spoor
Employees	138
Country	US
IPO Date	2005-11-10

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.